Does CONMED CORPORATION have an economic moat?

Based on its FY2025 SEC filings, the Moat Index scores CONMED CORPORATION (CNMD) 32.9 out of 100 — below the Shallow-moat bar, so no moat. The four filters behind that score (each 0–100): pricing power 92, returns on capital 0, balance-sheet safety 3, capital discipline 24.

Is CNMD stock trading below its intrinsic value?

Against a deliberately conservative owner-earnings model (9% discount rate, 0% assumed growth, capped at 4%), estimated intrinsic value is $16.37 per share versus a recent price of $43.20 — 164% above value. This is an educational estimate computed from primary SEC filings, not investment advice.

How has CNMD's Moat Score changed over time?

The record logs 3 readings since Jul 17, 2026; the latest reads 32.9 out of 100 (no moat). No tier changes on record yet. The history is append-only — readings are only ever added, never rewritten.

The Moat Index

CONMED CORPORATION

CNMD · Healthcare · $1.3B mkt cap · FY2025 filings · No moat ·

Doesn't clear the bar

No moat

The four filters

Pricing power92

Median gross margin 54.6% over 10y, very stable.

Returns on capital0

Median ROIC 4.7%, above the 9% hurdle in 0% of years.

Balance-sheet safety3

Net debt/EBITDA 7.7x, interest coverage 3x.

Capital discipline24

Owner earnings trend unclear, share count growing (dilution).

Margin of safety

Above valueOn sale

164% above value

Owner earnings (normalized): $45.4M
Est. intrinsic value / share: $16.37
Recent price: $43.20
Discount to value: 164% above value

Conservative model: 9% discount rate, 0% assumed growth (capped at 4%), maintenance capex ≈ min(capex, D&A).

18 years of fundamentals

The business, in plain English

CONMED CORPORATION booked $1.4B of revenue in FY2025 in the Healthcare sector and kept 54.6% of it as gross profit — a solid-margin business by that measure. After every other cost, 3.4% of each revenue dollar reached the bottom line.

Across the filed record, revenue grew from $694.7M (FY2009) to $1.4B (FY2025) — about 4.4% a year compounded over 16 years.

It earned 3.7% on invested capital in FY2025, with a median of 4.8% across 17 filed years. The Returns on Capital filter above scores it 0/100.

The balance sheet carried $834.9M of total debt in FY2025 against $27.2M of owner earnings — roughly 30.6 years of owner earnings to retire it all. Balance-Sheet Safety scores it 3/100.

The share count rose 10.1% between FY2011 and FY2025 — existing owners have been diluted over the record. Capital Discipline scores it 24/100.

Put together: Pricing Power is the strongest of the four filters (92/100) and Returns on Capital the weakest (0/100), which is how CNMD lands at 33/100 — a None moat.

This breakdown is generated from the filed numbers and sub-scores above — no outside narrative, no estimates. Where a filing doesn’t disclose an input, the sentence that would need it is omitted instead of guessed.

RevenueSales, as filed$1.4B FY2025

Gross marginRevenue kept after cost of goods54.6% FY2025

Return on invested capitalOperating profit on the capital employed3.7% FY2025

Owner earningsCash an owner could take out$27.2M FY2025

Gaps in a line mean that item isn’t in CNMD’s filings for that year — the series is never interpolated or estimated. The Table view lists every filed value, including operating and net margins, total debt, and share count.

Moat Score history

Moat Score over timeLast scored reading of each day, on the 0–100 scale32.9 / 100

Score history begins Jul 17, 2026 — the record builds from here and can’t be backfilled.

Tier changesSame-methodology crossings of the Wide / Narrow / Shallow bars

None yet — CNMD has read No moat for every logged capture since Jul 17, 2026.

Scores are logged append-only and never overwritten — this record can’t be backfilled, which is exactly why it’s worth keeping.

Healthcare context

#326 of 440 scored Healthcare companies, ranked by Moat Score.

Nearest peers by Moat Score

#324SGRY Surgery Partners, Inc.33.2 out of 100, No moatNo moat
#325FLGT Fulgent Genetics, Inc.33.2 out of 100, No moatNo moat
#327FEED ENvue Medical, Inc.32.9 out of 100, No moatNo moat
#328HRTX HERON THERAPEUTICS, INC. /DE/32.8 out of 100, No moatNo moat

Compare CNMD with its nearest peers →All Healthcare companies on the Index →

Common questions about CNMD

Does CONMED CORPORATION have an economic moat?: Based on its FY2025 SEC filings, the Moat Index scores CONMED CORPORATION (CNMD) 32.9 out of 100 — below the Shallow-moat bar, so no moat. The four filters behind that score (each 0–100): pricing power 92, returns on capital 0, balance-sheet safety 3, capital discipline 24.
Is CNMD stock trading below its intrinsic value?: Against a deliberately conservative owner-earnings model (9% discount rate, 0% assumed growth, capped at 4%), estimated intrinsic value is $16.37 per share versus a recent price of $43.20 — 164% above value. This is an educational estimate computed from primary SEC filings, not investment advice.
How has CNMD's Moat Score changed over time?: The record logs 3 readings since Jul 17, 2026; the latest reads 32.9 out of 100 (no moat). No tier changes on record yet. The history is append-only — readings are only ever added, never rewritten.

Embed this score on your site

One iframe, no script. The badge shows CNMD’s live Moat Score, updates itself as new filings are scored, and links back here. How it works.

<iframe
  src="https://buylikebuffett.com/embed/CNMD"
  width="340" height="150" style="border:0"
  title="CNMD Moat Score — The Moat Index"
  loading="lazy"></iframe>

Scored from primary SEC filings via the public methodology. Educational only — not a recommendation to buy or sell CNMD. See the disclaimer.